Recital 259, Decision_act (EU) 2004/104

In forcesince 27 Nov 2002

In its response to the statement of objections, Aventis points out that it has initiated extensive compliance programmes, which resulted in the disclosure of other agreements. It was a mistake that the methylglucamine agreement was not identified and disclosed to the Commission(152).